Multiple Myeloma | What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma
Research To Practice | Oncology Videos · Dr. Neil Love
October 9, 202347m 16s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Prof Philippe Moreau, including the following topics:
- Perspectives on efficacy outcomes with and toxicity profiles of daratumumab and isatuximab (0:00)
- Selection of an anti-CD38 antibody for initial treatment of multiple myeloma (MM) (7:28)
- Approach to maintenance therapy for transplant-eligible patients with MM (15:47)
- Management of MM in older patients; treatment approaches for t(11;14) MM (22:47)
- Management of relapsed/refractory MM (29:49)
- Management of anti-CD38 antibody-associated side effects (35:45)
- Other relevant clinical scenarios in MM — Plasma cell leukemia, smoldering myeloma (41:19)
- Perspectives on the future landscape of up-front treatment for MM (45:02)